Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Dermatology Research Associates

Neither a doctor nor a teaching hospital

Research payments

$5,005,697

765 payments

Through program year 2025, Dermatology Research Associates is reported as receiving $5,005,697 in research payments, across 765 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $1,224,429 136
2024 Research $1,002,362 174
2023 Research $387,235 165
2022 Research $975,262 65
2021 Research $538,103 55
2020 Research $337,504 55
2019 Research $540,803 115

Breakdown

Who paid Research payments · program years 2019–2025
  1. Amgen Inc. $1,805,001 23 payments
  2. Incyte Corporation $1,517,000 583 payments
  3. Sanofi US Services Inc. $556,215 43 payments
  4. E.R. Squibb & Sons, L.L.C. $430,795 5 payments
  5. LEO Pharma AS $401,157 67 payments
  6. Allergan Inc. $186,566 19 payments
  7. AbbVie, Inc. $70,245 12 payments
  8. Merck Sharp & Dohme Corporation $29,224 6 payments
  9. Celgene Corporation $4,541 2 payments
  10. Pfizer Inc. $2,495 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. P3 switching study PK; plaque psoriasis $429,758 1 payment
  2. A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) $372,885 1 payment
  3. Phase 2b POC PsO Study - A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study to Evaluate the Clinical Efficacy and Safety of BMS-986322 in Participants with Moderate-to-Severe Psoriasis $299,792 2 payments
  4. ASCEND P3 AD Extension $291,510 2 payments
  5. A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis $246,831 11 payments
  6. Long-Term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - Ecztend $227,181 26 payments
  7. A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo $223,132 15 payments
  8. Ph2b_chronic urticaria $187,466 5 payments
  9. JUVEDERM VOLITE XC Injectable Gel for Fine Lines on the Cheek $186,566 19 payments
  10. A Double Blind, Randomized, Dose Ranging Study of INCB018424 Phosphate Cream in Subjects With Vitiligo $185,486 33 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record